Tamoxifen 10 mg Tablets
- Pickup from New Mail
- New Mail Courier
- Pickup from the store
- Other transport services
- Cash upon receipt
- Bank transfer
- Privat 24
- WebMoney
- Tamoxifen 10 mg Tablets — Swiss Remedies
- Brand: Swiss Remedies
- Category: SERM Research Compound
- Content: 100 tablets 10 mg (1,000 mg total)
- Manufactured in: Switzerland
Product Overview
Tamoxifen 10 mg is a selective estrogen-receptor modulator (SERM) widely used in
endocrinology, oncology, and reproductive-physiology research. By antagonizing ER-/
receptors, tamoxifen reduces estrogenic negative feedback on the hypothalamic–pituitary–gonadal (HPG) axis,
thereby increasing luteinising hormone (LH), follicle-stimulating hormone (FSH), and endogenous testosterone
levels in male research models.
In female models, tamoxifen remains the reference anti-estrogen for ER-positive tumor studies
and is foundational in breast-cancer research methodologies. Its long half-life (parent: 4–11 days;
active metabolite endoxifen: 50–70 h) ensures stable receptor occupancy and consistent endocrine modulation.
Key Research Highlights
HPG-axis stimulation:
Studies show that 10–20 mg/day for 3 months can double serum testosterone in hypogonadal men (PMC).
Gynecomastia regression models:
Clinical literature demonstrates breast-tissue reduction with 10–20 mg/day during anabolic-steroid cycles.
Anti-estrogen gold standard:
Primary SERM model for ER-positive tumor studies and comparative endocrine research.
Pharmacokinetics:
~100% oral bioavailability; parent half-life 4–11 days; active metabolite half-life 50–70 h.
Research logistics:
Film-coated tablets stable 25 °C with 36-month shelf-life, simplifying storage compared to parenteral SERMs.
Suggested Laboratory Applications
- ER-/ modulation studies
- HPG-axis regulation and testosterone-restoration experiments
- Gynecomastia and anti-estrogenic pathway research
- ER-positive tumor and endocrine oncology models
- Comparative SERM pharmacology and metabolite profiling
Technical Specifications
| Field | Data |
|---|---|
| Chemical Name | Tamoxifen (base); supplied as Tamoxifen Citrate |
| Chemical Formula | C26H29NO (base) |
| Synonyms | Nolvadex; TMX; 4-(1-dimethylaminoethoxy)-diphenyl-1-ethenyl-phenol |
| Molecular Weight | 371.5 g/mol (base); 563.6 g/mol (citrate) |
| CAS Numbers | 10540-29-1 (base); 54965-24-1 (citrate) |
| PubChem-Documented Benefits | • Blocks ER feedback LH/FSH testosterone |
| • Standard SERM for ER-positive tumor research | • Gynecomastia regression documentation |
| Documented Risks / Side-Effects | Hot-flushes; transient visual changes; thrombo-embolism risk; cataract associations; |
| lipid shifts; reduced bone-mineral density | Total Active Compound |
| 1,000 mg tamoxifen base (10 mg 100 tablets) | Shelf-Life |
36 months (sealed; 25 °C; protect from light)
PubChem-Supported Research Insights
- Strong ER-blockade increases gonadotropin secretion
- Primary comparator in SERM and anti-estrogen studies
- Supports ER-positive cancer research and endocrine therapy modeling
- Long half-life enables extended receptor modulation
- Active metabolites contribute to prolonged efficacy and pharmacodynamics
Documented Research Side Effects
- Hot-flushes and vasomotor symptoms
- Visual blurring and reported cataract risk
- Thrombo-embolic events and lipid-profile shifts
- Reduced bone-mineral density during prolonged exposure
- Fatigue and mood changes reported in some literature
Handling & Compliance
For Research Use Only – not for dietary, therapeutic, or veterinary use.
Tamoxifen is prohibited under WADA S4 (Hormone Modulators); any exposure may trigger positive doping results.
Purchase confirms qualified-researcher status and acceptance of all handling liability.
Store sealed, protected from heat and light, and follow institutional chemical-safety protocols.
-
Package:100 tablets 10 mg (1.000 mg total)
-
Molecular formula:C26H29NO (base)
-
Country of manufacture:Switzerland